Role of sirtuin 2 (SIRT2) in the drug resistance of melanomas.

2015/17/B/NZ5/00142

Keywords

Descriptors

  • NZ5_1: Etiologia chorób człowieka
  • NZ2_2: Genomika, transkryptomika i epigenomika
  • NZ3_7: Przekaźnictwo sygnału

Panel

NZ5 – Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)

Host institution

Instytut Biologii Medycznej PAN

Voivodeship: łódzkie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr Marcin Marek Ratajewski

Number of co-investigators in the project: 4

Call

OPUS 9 – announced on 2015-03-16

Amount awarded
577 200 PLN
Project start date
2016-02-25
Project end date
2019-10-24
Project duration
44 months (the same as in the proposal)
Project status
Project settled

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

Publication in academic press/journals (2)

  1. Targeting SIRT2 Sensitizes Melanoma Cells to Cisplatin via an EGFR-Dependent Mechanism.

    Authors:
    Karwaciak I, Sałkowska A, Karaś K, Dastych J, Ratajewski M.
    Academic press:
    International Journal of Molecular Sciences (year: 2021, volume: 22(9), pages: 5034), Publisher: MDPI
    Status:
    Published
    DOI:
    10.3390/ijms22095034 – link to the publication
  2. SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib.

    Authors:
    Karwaciak I, Sałkowska A, Karaś K, Sobalska-Kwapis M, Walczak-Drzewiecka A, Pułaski Ł, Strapagiel D, Dastych J, Ratajewski M.
    Academic press:
    Cancers (Basel) (year: 2019, volume: 11(5), pages: pii: E673), Publisher: MDPI
    Status:
    Published
    DOI:
    10.3390/cancers11050673 – link to the publication

« New search

Graphic design and implementation: Jakub Piotrowski